Cardiometabolic Risk reduction by rimonabant: the effectiveness in daily practice and its use.

Trial Profile

Cardiometabolic Risk reduction by rimonabant: the effectiveness in daily practice and its use.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Feb 2013

At a glance

  • Drugs Rimonabant (Primary)
  • Indications Hyperglycaemia; Obesity; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms CARDIO-REDUSE
  • Most Recent Events

    • 04 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top